Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedJan 10, 2026
DataAggregated Company Financials
Companies317
  • 7D0.3%
  • 3M19.6%
  • 1Y25.8%
  • YTD0.3%

The Pharma is pretty flat in the last 7 days, but Regencell Bioscience Holdings has stood out, gaining 123%. The past year has been better, since the industry has gained 26% in that time. Earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 10 Jan 2026US$2.3tUS$402.6bUS$71.5b19.6x32x5.7x
Mon, 08 Dec 2025US$2.2tUS$402.8bUS$71.4b19.5x30.2x5.3x
Wed, 05 Nov 2025US$1.9tUS$395.4bUS$70.7b17.7x27.4x4.9x
Fri, 03 Oct 2025US$1.9tUS$387.9bUS$60.9b19.8x31.4x4.9x
Sun, 31 Aug 2025US$1.8tUS$387.9bUS$61.0b20x29.1x4.6x
Tue, 29 Jul 2025US$1.8tUS$384.0bUS$62.2b17.7x29.2x4.7x
Thu, 26 Jun 2025US$1.7tUS$382.7bUS$61.2b18.3x28.2x4.5x
Sat, 24 May 2025US$1.6tUS$382.6bUS$61.2b17.2x26.9x4.3x
Mon, 21 Apr 2025US$1.7tUS$380.6bUS$48.4b16.1x36x4.6x
Wed, 19 Mar 2025US$1.9tUS$380.5bUS$35.1b16.3x53.2x4.9x
Fri, 14 Feb 2025US$1.9tUS$380.9bUS$39.0b18.2x48x4.9x
Sun, 12 Jan 2025US$1.8tUS$368.6bUS$31.1b17.2x58x4.9x
Tue, 10 Dec 2024US$1.9tUS$373.8bUS$30.6b19.3x61.3x5x
Thu, 07 Nov 2024US$1.9tUS$373.5bUS$29.7b19.9x63.4x5x
Sat, 05 Oct 2024US$2.0tUS$364.1bUS$25.2b18.5x78.4x5.4x
Mon, 02 Sep 2024US$2.1tUS$364.1bUS$25.5b18.1x81.5x5.7x
Wed, 31 Jul 2024US$1.9tUS$357.6bUS$12.9b16.2x150.5x5.4x
Fri, 28 Jun 2024US$2.0tUS$357.6bUS$14.0b16x140.2x5.5x
Sun, 26 May 2024US$1.9tUS$358.3bUS$14.1b17.9x133.7x5.2x
Tue, 23 Apr 2024US$1.8tUS$357.7bUS$29.8b20.6x59.9x5x
Thu, 21 Mar 2024US$1.9tUS$355.4bUS$22.5b20.2x83.9x5.3x
Sat, 17 Feb 2024US$1.9tUS$355.0bUS$23.9b28.3x78.6x5.3x
Mon, 15 Jan 2024US$1.8tUS$375.2bUS$33.9b26.3x52.6x4.7x
Wed, 13 Dec 2023US$1.7tUS$375.1bUS$33.9b26.7x48.9x4.4x
Fri, 10 Nov 2023US$1.7tUS$375.2bUS$34.0b26.2x49.1x4.5x
Sun, 08 Oct 2023US$1.7tUS$381.8bUS$43.8b18.5x38.2x4.4x
Tue, 05 Sep 2023US$1.7tUS$381.4bUS$43.7b19.6x39.7x4.5x
Thu, 03 Aug 2023US$1.7tUS$379.1bUS$44.0b18.7x38.5x4.5x
Sat, 01 Jul 2023US$1.8tUS$392.8bUS$60.2b18.7x29.2x4.5x
Mon, 29 May 2023US$1.7tUS$392.9bUS$60.6b17.8x27.6x4.3x
Wed, 26 Apr 2023US$1.7tUS$402.7bUS$63.2b17.2x26.3x4.1x
Fri, 24 Mar 2023US$1.5tUS$401.1bUS$69.3b15.3x22.2x3.8x
Sun, 19 Feb 2023US$1.6tUS$401.8bUS$68.4b18.8x23.9x4.1x
Tue, 17 Jan 2023US$1.7tUS$403.7bUS$70.7b17.6x24.6x4.3x
Price to Earnings Ratio

24.6x


Total Market Cap: US$1.7tTotal Earnings: US$70.7bTotal Revenue: US$403.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 32.0x which is lower than its 3-year average PE of 53.0x.
  • The 3-year average PS ratio of 4.8x is lower than the industry's current PS ratio of 5.7x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.82%
Healthcare2.00%
Pharma0.30%
Pharma0.30%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RGC Regencell Bioscience HoldingsUS$45.79122.9%
+US$12.5b		35,894.2%PB4658.7x
MRK MerckUS$110.533.8%
+US$10.1b		11.4%PE14.4x
BMY Bristol-Myers SquibbUS$55.864.5%
+US$4.9b		0.05%PE18.8x
PFE PfizerUS$25.481.2%
+US$1.7b		-4.6%PE14.8x
NBY NovaBay PharmaceuticalsUS$19.16226.4%
+US$1.7b		2,648.9%PS234.4x

Latest News

ELVN
US$26.00
Enliven Therapeutics
7D
67.3%
1Y
19.6%
AQST
US$3.91
Aquestive Therapeutics
7D
-39.4%
1Y
26.9%
JAZZ
US$161.13
Jazz Pharmaceuticals
7D
-6.9%
1Y
32.7%
MRK
US$110.53
Merck
7D
3.8%
1Y
11.4%

MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes

Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.
JNJ
US$204.39
Johnson & Johnson
7D
-1.4%
1Y
43.9%

JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward

Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.
LLY
US$1,063.56
Eli Lilly
7D
-1.6%
1Y
33.0%
BMY
US$55.86
Bristol-Myers Squibb
7D
4.5%
1Y
0.05%

BMY: Sector Tailwinds And Pipeline Milestones Will Shape Next Share Rerating

Analysts have nudged their price targets for Bristol Myers Squibb higher, with moves such as UBS shifting to a Buy rating with a US$65 target from US$46 and Citi lifting its target to US$53 from US$45. This reflects growing confidence tied to sector tailwinds, improving deal activity, and a refreshed view of the company’s valuation and earnings power.
TERN
US$35.48
Terns Pharmaceuticals
7D
-11.5%
1Y
608.2%
CRMD
US$7.63
CorMedix
7D
-37.3%
1Y
-31.8%
AXSM
US$169.38
Axsome Therapeutics
7D
-5.2%
1Y
111.6%

AXSM: Late-Stage CNS Franchise And AXS-05 Readout Will Drive Upside

Narrative Update: Axsome Therapeutics Analysts have lifted their average price target for Axsome Therapeutics by about $15 per share, citing recent model updates that reflect slightly higher revenue growth assumptions, a modestly richer future P/E multiple, and Street research pointing to steady commercial progress for Auvelity, Symbravo and Sunosi, along with potential upside from the AXS-05 program. Analyst Commentary Bullish analysts are generally constructive on Axsome Therapeutics, pointing to product execution, model updates and potential pipeline upside as reasons for lifting their valuation work.
PFE
US$25.48
Pfizer
7D
1.2%
1Y
-4.6%

Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43

Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
ALMS
US$19.56
Alumis
7D
118.4%
1Y
179.4%
WVE
US$13.84
Wave Life Sciences
7D
-13.2%
1Y
19.9%

WVE: INHBE Obesity Program Will Drive Future Upside Potential

Analysts have inched up their fair value estimate for Wave Life Sciences to about $31.93 per share from $31.60. This reflects updated views on the company’s INHBE-targeting obesity program, strengthened competitive position in AATD, and continued interest in its broader genetic medicines pipeline.
TEVA
US$32.01
Teva Pharmaceutical Industries
7D
3.4%
1Y
52.9%
RGC
US$45.79
Regencell Bioscience Holdings
7D
122.9%
1Y
35,894.2%
NBY
US$19.16
NovaBay Pharmaceuticals
7D
226.4%
1Y
2,648.9%